GlassScriptPhysician profile
Joseph L Maccarone
NPI 1447272927
$1,650.32
in general payments reported to CMS, 2019-2025
13 companies · $412 in 2025
The $412 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $234 · 2021: $235 · 2022: $479 · 2023: $83.44 · 2024: $58.98 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $504.08 | 2021-2025 | Interstim |
| Medtronic USA, INC. | $223.04 | 2019-2020 | |
| Astellas Pharma US INC | $178.95 | 2021-2023 | Myrbetriq |
| Caldera Medical, INC | $148.04 | 2021-2022 | |
| Coloplast Corp | $135.32 | 2025 | |
| Pfizer INC. | $129.04 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $90.79 | 2023-2025 | Gemtesa |
| Axonics, INC. | $72.01 | 2022-2023 | Bulkamid, Axonics |
| Boston Scientific Corporation | $53.92 | 2019-2024 | Advantage System |
| Therapeuticsmd, INC. | $41.35 | 2019-2020 | |
| Bluewind Medical | $39.88 | 2025 | |
| Amag Pharmaceuticals, INC. | $21.32 | 2019 | |
| Urovant Sciences INC | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Maccarone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.